StudyGraphics #VisualAbstract CASTOR trial follow-up: Health-related quality of life was maintained in patients treated with daratumumab, bortezomib, and dexamethasone over time for relapsed or refractory multiple myeloma March 4, 2021 | Kathleen Lau Facebook Twitter Pinterest WhatsApp Linkedin ReddIt Email Print RELATED ARTICLESMORE FROM AUTHOR #VisualAbstract: Protection from SARS-CoV-2 re-infection may be diminished among elderly individuals #VisualAbstract: Tislelizumab plus chemotherapy improves outcomes for advanced squamous non small cell lung cancer over chemotherapy alone #VisualAbstract Rituximab plus high-dose chemotherapy (MegaCHOEP) show similar long-term efficacy to conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma
